321 related articles for article (PubMed ID: 21358064)
21. [Bisphosphonates (BP) and osteonecrosis of the jaws; should administration of BP be discontinued at the early phase?].
Urade M
Clin Calcium; 2010 Nov; 20(11):1740-3. PubMed ID: 21066911
[No Abstract] [Full Text] [Related]
22. A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates.
Thumbigere-Math V; Tu L; Huckabay S; Dudek AZ; Lunos S; Basi DL; Hughes PJ; Leach JW; Swenson KK; Gopalakrishnan R
Am J Clin Oncol; 2012 Aug; 35(4):386-92. PubMed ID: 22561331
[TBL] [Abstract][Full Text] [Related]
23. Management of patients on bisphosphonates and prevention of bisphosphonate-related osteonecrosis of the jaw.
Chu V; ;
Hawaii Dent J; 2008; 39(5):9-12; quiz 17. PubMed ID: 19189512
[TBL] [Abstract][Full Text] [Related]
24. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
O'Ryan FS; Khoury S; Liao W; Han MM; Hui RL; Baer D; Martin D; Liberty D; Lo JC
J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404
[TBL] [Abstract][Full Text] [Related]
25. Treatment results of bisphosphonate-related osteonecrosis of the jaws.
Wutzl A; Biedermann E; Wanschitz F; Seemann R; Klug C; Baumann A; Watzinger F; Schicho K; Ewers R; Millesi G
Head Neck; 2008 Sep; 30(9):1224-30. PubMed ID: 18642292
[TBL] [Abstract][Full Text] [Related]
26. American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-Related Osteonecrosis of the Jaws-2009 update: the need to refine the BRONJ definition.
Colella G; Campisi G; Fusco V
J Oral Maxillofac Surg; 2009 Dec; 67(12):2698-9. PubMed ID: 19925998
[No Abstract] [Full Text] [Related]
27. Bisphosphonate associated osteonecrosis of the jaws and endodontic treatment: two case reports.
Fugazzotto PA; Lightfoot S
J Mass Dent Soc; 2006; 55(2):5. PubMed ID: 16937899
[No Abstract] [Full Text] [Related]
28. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
Grewal VS; Fayans EP
Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
[TBL] [Abstract][Full Text] [Related]
29. [Bisphosphonates (BP) and osteonecrosis of the jaws; continuous treatment with Bisphosphonates should be considered].
Mawatari T
Clin Calcium; 2010 Nov; 20(11):1743-7. PubMed ID: 21066910
[No Abstract] [Full Text] [Related]
30. Bisphosphonates and bisphosphonate induced osteonecrosis.
Sawatari Y; Marx RE
Oral Maxillofac Surg Clin North Am; 2007 Nov; 19(4):487-98, v-vi. PubMed ID: 18088900
[TBL] [Abstract][Full Text] [Related]
31. Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center.
Nicolatou-Galitis O; Papadopoulou E; Sarri T; Boziari P; Karayianni A; Kyrtsonis MC; Repousis P; Barbounis V; Migliorati CA
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 Aug; 112(2):195-202. PubMed ID: 21622014
[TBL] [Abstract][Full Text] [Related]
32. The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw.
Wilde F; Heufelder M; Winter K; Hendricks J; Frerich B; Schramm A; Hemprich A
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 Feb; 111(2):153-63. PubMed ID: 20674411
[TBL] [Abstract][Full Text] [Related]
33. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ
J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
[TBL] [Abstract][Full Text] [Related]
34. Bisphosphonate-related osteonecrosis of the jaws--an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma.
Curi MM; Cossolin GS; Koga DH; Zardetto C; Christianini S; Feher O; Cardoso CL; dos Santos MO
J Oral Maxillofac Surg; 2011 Sep; 69(9):2465-72. PubMed ID: 21763050
[TBL] [Abstract][Full Text] [Related]
35. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
37. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update.
Ruggiero SL; Dodson TB; Assael LA; Landesberg R; Marx RE; Mehrotra B;
Aust Endod J; 2009 Dec; 35(3):119-30. PubMed ID: 19961450
[No Abstract] [Full Text] [Related]
38. Bisphosphonate-related osteonecrosis of the jaws: how to manage cancer patients.
Madrid C; Bouferrache K; Abarca M; Jaques B; Broome M
Oral Oncol; 2010 Jun; 46(6):468-70. PubMed ID: 20452814
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases.
Grant BT; Amenedo C; Freeman K; Kraut RA
J Oral Maxillofac Surg; 2008 Feb; 66(2):223-30. PubMed ID: 18201600
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonate-related osteonecrosis of the jaw associated with dental implants.
Lazarovici TS; Yahalom R; Taicher S; Schwartz-Arad D; Peleg O; Yarom N
J Oral Maxillofac Surg; 2010 Apr; 68(4):790-6. PubMed ID: 20307764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
